SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
SEPTEMBER 23, 1999
----------------------
(Date of Report)
ENTROPIN, INC.
-----------------------------------------------------
(Exact Name of Registrant as specified in its charter)
COLORADO 33-23693 84-1090424
---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 OASIS STREET, INDIO, CA 92201
------------------------------------------------------------
(Address of principal executive offices including zip code)
(760) 775-8333
--------------------------------------------------
(Registrant's telephone number including area code)
N/A
------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
- ---------------------
Lois Rezler announced her resignation as Vice President of Scientific
and Regulatory Affairs of Entropin, Inc., effective September 12, 1999.
Western Center for Clinical Studies, Inc., a California corporation, will
continue to perform the scientific and regulatory affairs functions on
behalf of Entropin, Inc.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: September 23, 1999 ENTROPIN, INC.
By /s/ Don Hunter
-------------------------------
Donald Hunter
Chief Executive Officer
-2-
